首页> 外文期刊>Drug Metabolism and Disposition: The Biological Fate of Chemicals >Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance.
【24h】

Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance.

机译:右美沙芬与右美沙芬的尿代谢比不能反映右美沙芬的口腔清除率。

获取原文
获取原文并翻译 | 示例
           

摘要

Dextromethorphan urinary metabolic ratio is widely used to determine the CYP2D6 phenotype, but its utility to reflect subtle differences in catalytic activity is unclear. We evaluated the capability of dextromethorphan urinary metabolic ratio to predict dextromethorphan oral clearance as a measure of CYP2D6 activity. Data from 10 healthy extensive metabolizers of CYP2D6 were given 30 mg of dextromethorphan hydrobromide orally on two occasions. Blood and urine samples were collected for 72 h. Dextromethorphan and dextrorphan were determined in urine by high-performance liquid chromatography with fluorescence detection and in serum by liquid chromatography-mass spectrometry. The urinary metabolic ratio was very weakly correlated with dextromethorphan oral clearance (r = 0.24; p = 0.04). In contrast, the dextromethorphan oral clearance was highly correlated with the dextromethorphan to dextrorphan area under the concentration-time curve ratio (r = 0.84; p = 0.005) and the 3-h (r = 0.60; p = 0.003), 4-h (r= 0.72, p < 0.001), 6-h (r = 0.67; p < 0.001), and 8-h (r = 0.74; p < 0.001) dextromethorphan to dextrorphan serum ratios. Assuming an effect size of 30%, the number of volunteers required for crossover and cross-sectional studies using the urinary metabolic ratio as the CYP2D6 index was calculated to be 56 and 524, respectively, whereas 14 and 60 subjects are needed if oral clearance is used. Considering the required sample size and the low correlation with oral clearance, urinary metabolic ratio is not recommended as the primary outcome variable in studies requiring the detection of modest changes in CYP2D6 activity.
机译:右美沙芬尿液代谢率被广泛用于确定CYP2D6表型,但其能否反映催化活性的细微差别尚不清楚。我们评估了右美沙芬尿液代谢比率预测右美沙芬口服清除率的能力,以此作为CYP2D6活性的量度。两次口服10种健康的CYP2D6广泛代谢者的数据,分别口服30 mg氢溴酸右美沙芬。收集血液和尿液样本72小时。高效液相色谱-荧光检测法测定尿液中的右美沙芬和右美沙芬,液相色谱-质谱法测定血清中的右美沙芬和右美沙芬。尿中代谢率与右美沙芬口服清除率的相关性非常弱(r = 0.24; p = 0.04)。相反,在浓度-时间曲线比率(r = 0.84; p = 0.005)和3-h(r = 0.60; p = 0.003),4-h下,右美沙芬的口腔清除率与右美沙芬与右美沙芬的面积高度相关。 (r = 0.72,p <0.001),6-h(r = 0.67; p <0.001)和8-h(r = 0.74; p <0.001)右美沙芬与右啡烷的血清比率。假设效应大小为30%,使用尿代谢比作为CYP2D6指数进行交叉和横断面研究所需的志愿者人数分别计算为56和524,而如果需要口腔通便,则需要14和60名受试者用过的。考虑到所需的样本量以及与口腔清除率的相关性低,在需要检测CYP2D6活性适度变化的研究中,不建议将尿代谢比作为主要结局变量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号